Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 16/20 | 0.68 |
| ▸ | PDK2 | Q15119 | 16/20 | 0.68 |
| ▸ | PDK3 | Q15120 | 16/20 | 0.68 |
| ▸ | PDK4 | Q16654 | 16/20 | 0.68 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL618106 | 0.98 | PDK1 (0.70) | PDK1PDK2PDK3PDK4CA1 | |
| SCHEMBL28091743 | 0.83 | PDK1 (0.69) | PDK1PDK2PDK3PDK4 | |
| SCHEMBL8116203 | 0.81 | KMT2A (0.56) | PDK1PDK2PDK3PDK4KMT2A | |
| SCHEMBL10827862 | 0.81 | PDK1 (0.70) | PDK1PDK2PDK3PDK4MEN1 | |
| SCHEMBL2069741 | 0.81 | MEN1 (0.55) | PDK1PDK2PDK3PDK4CA1 | |
| SCHEMBL3294939 | 0.81 | PDK1 (0.49) | PDK1PDK2PDK3PDK4CA1 | |
| SCHEMBL9384576 | 0.80 | PDK1 (0.50) | PDK1PDK2PDK3PDK4CA1 | |
| SCHEMBL15072455 | 0.80 | MAPK1 (0.55) | PDK1PDK2PDK3PDK4MEN1 | |
| SCHEMBL3717777 | 0.77 | PDK1 (0.55) | PDK1PDK2PDK3PDK4TRPV1 | |
| SCHEMBL9321885 | 0.76 | PDK1 (0.63) | PDK1PDK2PDK3PDK4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140840-A1 | -G(V)-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | Bayer Corporation (US) | 2001-10-10 | — | — | EP | disclosed |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-23 | — | — | US | disclosed |
| WO-2000042012-A1 | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | PDK1 1406/4885PDK2 734/4885PDK3 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.